持续血糖监测市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024年，全球持续血糖监测市场规模达109亿美元，预计到2034年将以16%的复合年增长率增长，达到471亿美元，这主要得益于糖尿病患病率的上升以及对实时、用户友好型监测技术的需求。 CGM系统能够全天候追踪血糖水平，在各种医疗保健领域越来越受欢迎。这些系统通常使用放置在皮下的微创感测器来监测间质血糖，并将资料传输到数位装置以便于追踪。

随着糖尿病管理意识的不断提升以及全球向预防保健的转变，连续血糖监测 (CGM) 系统的普及率正在迅速提升。越来越多的患者和医疗保健专业人员选择 CGM 解决方案，以更好地控制血糖、减少併发症并改善长期健康。即时持续监测血糖水平的能力，以及智慧警报和数据共享功能，正在透过为患者提供切实可行的洞察，彻底改变糖尿病护理。随着全球医疗保健系统强调以患者为中心、以技术支援的解决方案，CGM 技术正逐渐成为现代糖尿病管理的基石。

感测器精度和功能的不断提升，在CGM市场的转型中发挥了关键作用。 2024年，感测器细分市场产值达到55亿美元，预计到2034年将以16.1%的复合年增长率成长。生物感测器技术的进步使得更小、更精确的感测器成为可能，它们不仅可以监测血糖，还可以追踪其他生物标记物，从而更全面地了解使用者的代谢健康状况。更高的舒适度、更高的资料精度和更佳的可穿戴性促使用户从传统的血糖监测方法转向CGM系统。

家庭护理已成为主要的应用领域，得益于这些系统提供的便利性，到2024年，其市场规模将达到88亿美元，占81%的市场份额。即时警报、与智慧型手机的整合以及与医疗保健专业人员轻鬆共享资料的功能，使CGM设备成为居家管理糖尿病患者的实用之选。此外，远距照护的转变进一步提高了CGM设备的采用率，消费者对减少对就诊依赖的居家监控解决方案表现出强烈的偏好。

2024年，美国持续血糖监测市场规模达49亿美元，这得益于糖尿病患者人数的不断增长以及保险覆盖范围的扩大，从而提高了持续血糖监测系统的价格和可及性。此外，医疗保险政策的扶持和报销范围的扩大也使得CGM系统的应用范围更加广泛，包括老年人和低收入群体。同时，美国市场也受惠于穿戴式健康科技的持续创新，感测器体积更小、配戴更舒适，配戴时间更长，资料准确性也更高。

全球连续血糖监测市场的知名公司包括 Dexcom、美敦力、雅培实验室、Senseonics、罗氏製药、三诺生物、Med Trust、Medtrum Technologies、浙江凯立德、i-SENS 和 A. Menarini Diagnostics。为了提升市场占有率，连续血糖监测 (CGM) 製造商投入研发资金，开发精度更高、尺寸更小、佩戴时间更长的下一代感测器。许多製造商正在与数位健康平台和行动应用程式开发商建立策略联盟，以增强设备连接性和资料整合。其他製造商则透过区域合作伙伴关係和收购小型企业来扩大其全球影响力，以丰富产品组合併加快创新速度。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 全球糖尿病患者人数不断增加
    • 全球对连续监测设备的需求不断增长
    • 设备技术进步
    • 政府加强提高人们对糖尿病的认识
  • 产业陷阱与挑战
    • 与设备相关的高成本
    • 严格的监管情景
• 成长潜力分析
• 监管格局
• 川普政府关税
  • 对贸易的影响
    • 贸易量中断
    • 各国应对措施
  • 对产业的影响
    • 供应方影响（製造成本）
      • 主要材料价格波动
      • 供应链重组
      • 生产成本影响
    • 需求面影响（消费者成本）
      • 价格传导至终端市场
      • 市占率动态
      • 消费者反应模式
  • 受影响的主要公司
  • 策略产业反应
    • 供应链重组
    • 定价和产品策略
    • 政策参与
  • 展望与未来考虑
• 技术格局
• 未来市场趋势
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按组成部分，2021 年至 2034 年

• 主要趋势
• 发射器
• 感应器
• 接收器

第六章：市场估计与预测：依最终用途，2021 年至 2034 年

• 主要趋势
• 医院
• 居家照护环境
• 诊断中心和诊所
• 其他最终用途

第七章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙
  • 荷兰
  • 瑞典
  • 俄罗斯
  • 丹麦
  • 芬兰
  • 挪威
  • 波兰
  • 瑞士
  • 比利时
  • 立陶宛
  • 拉脱维亚
  • 爱沙尼亚
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 台湾
  • 印尼
  • 越南
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 哥伦比亚
  • 智利
  • 秘鲁
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 以色列
  • 科威特
  • 卡达

第八章：公司简介

• Abbott Laboratories
• A. Menarini Diagnostics
• Dexcom
• i-SENS
• F. Hoffmann-La Roche
• Med Trust
• Medtronic
• Medtrum Technologies
• Senseonics
• Sinocare
• Zhejiang POCTech

The Global Continuous Glucose Monitoring Market was valued at USD 10.9 billion in 2024 and is estimated to grow at a CAGR of 16% to reach USD 47.1 billion by 2034, driven by the increasing prevalence of diabetes and the demand for real-time, user-friendly monitoring technologies. CGM systems, which allow round-the-clock tracking of glucose levels, are gaining traction across various healthcare settings. These systems typically use a minimally invasive sensor placed beneath the skin to monitor interstitial glucose, transmitting the data to digital devices for easy tracking.

With rising awareness about diabetes management and the global shift toward preventive care, the adoption of continuous glucose monitoring (CGM) systems is accelerating rapidly. Both patients and healthcare professionals are increasingly turning to CGM solutions to enable better glycemic control, reduce complications, and improve long-term health outcomes. The ability to continuously monitor glucose levels in real time, along with smart alerts and data-sharing capabilities, is transforming diabetes care by empowering individuals with actionable insights. As healthcare systems worldwide emphasize patient-centered and tech-enabled solutions, CGM technology is emerging as a cornerstone of modern diabetes management.

The continuous improvements in sensor accuracy and functionality have played a key role in transforming the CGM market. In 2024, the sensors segment generated USD 5.5 billion and is expected to grow at a CAGR of 16.1% through 2034. Advancements in biosensor technology have enabled smaller, more precise sensors that not only monitor glucose but can also track other biomarkers, offering a broader view of the user's metabolic health. Increased comfort, enhanced data precision, and better wearability prompt users to transition from traditional glucose monitoring methods to CGM systems.

Home care has emerged as a primary application area, contributing USD 8.8 billion and holding an 81% share in 2024, fueled by the convenience these systems offer. Real-time alerts, integration with smartphones, and the ability to easily share data with healthcare professionals make CGM devices a practical choice for patients managing diabetes at home. In addition, shifts toward remote care have further increased adoption, with consumers showing a strong preference for at-home monitoring solutions that reduce dependence on clinical visits.

United States Continuous Glucose Monitoring Market accounted for USD 4.9 billion in 2024, driven by the rising number of people living with diabetes and greater insurance coverage that has improved the affordability and accessibility of CGM systems. Supportive Medicare policies and reimbursement expansions have enabled broader patient adoption, including among seniors and low-income groups. At the same time, the U.S. market is benefiting from continuous innovation in wearable health tech, leading to smaller, more comfortable sensors with extended wear time and enhanced data accuracy.

Prominent companies in the Global Continuous Glucose Monitoring Market include Dexcom, Medtronic, Abbott Laboratories, Senseonics, F. Hoffmann-La Roche, Sinocare, Med Trust, Medtrum Technologies, Zhejiang POCTech, i-SENS, and A. Menarini Diagnostics. To enhance market presence, CGM manufacturers invest in R&D to develop next-generation sensors with improved accuracy, smaller sizes, and longer wear times. Many are forming strategic alliances with digital health platforms and mobile app developers to enhance device connectivity and data integration. Others are expanding their global footprint through regional partnerships and acquiring smaller firms to diversify product portfolios and speed up innovation.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing number of people suffering from diabetes across the world
    • 3.2.1.2 Rise in demand for continuous monitoring devices globally
    • 3.2.1.3 Technological advancements in devices
    • 3.2.1.4 Increasing government initiatives to generate awareness regarding diabetes
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost related to devices
    • 3.2.2.2 Stringent regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on trade
    • 3.5.1.1 Trade volume disruptions
    • 3.5.1.2 Country-wise response
  • 3.5.2 Impact on the industry
    • 3.5.2.1 Supply-side impact (Cost of Manufacturing)
      • 3.5.2.1.1 Price volatility in key materials
      • 3.5.2.1.2 Supply chain restructuring
      • 3.5.2.1.3 Production cost implications
    • 3.5.2.2 Demand-side impact (Cost to Consumers)
      • 3.5.2.2.1 Price transmission to end markets
      • 3.5.2.2.2 Market share dynamics
      • 3.5.2.2.3 Consumer response patterns
  • 3.5.3 Key companies impacted
  • 3.5.4 Strategic industry responses
    • 3.5.4.1 Supply chain reconfiguration
    • 3.5.4.2 Pricing and product strategies
    • 3.5.4.3 Policy engagement
  • 3.5.5 Outlook and future considerations
• 3.6 Technological landscape
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Component, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Transmitters
• 5.3 Sensors
• 5.4 Receivers

Chapter 6 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Hospitals
• 6.3 Home care settings
• 6.4 Diagnostic centres and clinics
• 6.5 Other end use

Chapter 7 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 France
  • 7.3.3 UK
  • 7.3.4 Italy
  • 7.3.5 Spain
  • 7.3.6 Netherlands
  • 7.3.7 Sweden
  • 7.3.8 Russia
  • 7.3.9 Denmark
  • 7.3.10 Finland
  • 7.3.11 Norway
  • 7.3.12 Poland
  • 7.3.13 Switzerland
  • 7.3.14 Belgium
  • 7.3.15 Lithuania
  • 7.3.16 Latvia
  • 7.3.17 Estonia
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 South Korea
  • 7.4.6 Taiwan
  • 7.4.7 Indonesia
  • 7.4.8 Vietnam
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
  • 7.5.4 Colombia
  • 7.5.5 Chile
  • 7.5.6 Peru
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 UAE
  • 7.6.4 Israel
  • 7.6.5 Kuwait
  • 7.6.6 Qatar

Chapter 8 Company Profiles

• 8.1 Abbott Laboratories
• 8.2 A. Menarini Diagnostics
• 8.3 Dexcom
• 8.4 i-SENS
• 8.5 F. Hoffmann-La Roche
• 8.6 Med Trust
• 8.7 Medtronic
• 8.8 Medtrum Technologies
• 8.9 Senseonics
• 8.10 Sinocare
• 8.11 Zhejiang POCTech